Screener / SEC EDGAR /CIK 0001991792 /10-K filed Feb 27, 2026, compared with Mar 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

CG Oncology, Inc. CGON

Compare with peers Embed
SEC comment letters, last 20 years

1 review of CGON's filings by SEC staff

UPLOAD and CORRESP
Reviews 1 latest letter Nov 24, 2023
Questions asked 16 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 2 UPLOAD
  2. 2. Questions in them 16 numbered comments
  3. 3. Company replies 2 CORRESP
  4. 4. Reviews closed 0 of 1 closing letter

Form S-1

2023-11-24 to 2024-01-05 · 16 questions · 2 letters from the SEC, 2 from the company
No closing letter
Results discussion (MD&A)Critical estimatesRisk factors
Prospectus Summary · Overview, page 1
SEC asked (1)
Please revise your prospectus summary to explain briefly at first use each of the scientific or technical terms. By way of example only, we note the following terms: • Transurethral resection • In situ • Duration of response
CGON answered
Rule 83 Confidential Treatment Requested by CG Oncology, Inc. This letter is furnished supplementally on behalf of CG Oncology, Inc. (the “Company”) in response to comments from the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) received by letter dated November 24, 2023, and in connection with the review by the Commission of the above-mentioned Registration Statement on Form S-1 (the “Registration Statement”).
Rest of the letter

To assist the Staff in its review, the Company advises the Staff that it presently estimates, considering information currently available and current market conditions and based in part on information received by the lead underwriters, that the initial public offering price per share for the initial public offering (“IPO”) pursuant to the Registration Statement will be between $[***] and $[***] (without giving effect to any reverse stock split that the Company will effect prior to the offering, the “Preliminary Price Range”). For clarity, the Company advises the Staff that, given the volatility of the public trading markets and the uncertainty of the timing of the IPO, the Company and the lead underwriters have not yet finally agreed to a price range for the IPO. The Company advises the Staff that the final range to be included in a pre-effective amendment to the Registration Statement, after giving effect to an appropriate stock split, will include a price range of no more than $2.00 or 20% of the high end of the range, unless otherwise approved by the Staff. The Company’s grants of stock options during the 12 months preceding the latest balance sheet date presented in the Registration Statement, as well as those made since the latest balance sheet, are set forth below. The Company has historically determined the fair value of its common stock using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately Held Company Equity Securities Issued as Compensation (the “AICPA Practice Guide”). In addition, the Company’s Board of Directors (the “Board”) considered numerous objective and subjective factors, along with input from management and third-party valuations, to determine the fair value of the Company’s common stock as further disclosed on pages 98 and 99 of the Registration Statement. Based on the Company’s early stage of development, the difficulty in predicting the range of specific outcomes (and their likelihood) and other relevant factors, a hybrid method computing the probability-weighted value across two scenarios (the Current Value Method scenario and the Option Pricing Method (“OPM”) scenario) was considered most appropriate for valuations prior to April 2023. In addition, as a result of the closings of the Company’s Series E redeemable convertible preferred stock financing in September and October 2022, in the valuation completed in September 2022 effective as of June 30, 2022, the Company used the backsolve method to determine equity value in the OPM scenario. The backsolve method is a market approach that derives an implied total equity value from the sale price of the Company’s equity securities in a recent arm’s length transaction. For valuations performed on and after April 2023, the Company used a hybrid method of the Probability-Weighted Expected Return Method (“PWERM”) and OPM depending on the scenario, as the Company believed it could reasonably estimate potential future liquidity outcomes given the late clinical-stage nature of its product candidate, cretostimogene, as well as having better visibility into the timing of a potential IPO. The PWERM is a scenario-based analysis that estimates the value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes considered by the Company, as well as the economic and control rights of each share class. In addition, in certain cases the valuations took into account secondary sales of the Company’s common stock. As shown below, the PWERM applied probabilities to four possible outcomes: (i) a remain private (i.e., the Company remained a private enterprise) (the “Remain Private Scenario”); (ii) an IPO as of January 31, 2024, February 28, 2024 or April 30, 2024, as applicable (the “Early IPO Scenario”); (iii) an IPO as of June 30, 2024 or September 30, 2024, as applicable (the “Late IPO Scenario” and together with the Early IPO Scenario, the “IPO Scenarios”); and (iv) dissolution. In determining the enterprise value for the Remain Private scenarios, the Company applied the OPM backsolve method to the Company’s Series F redeemable convertible preferred stock financing in July 2023. For each IPO Scenario, the Company estimated its equity value based on, among other things, the value of public companies deemed similar to the Company at the time of their IPOs and/or investor and underwriter feedback following testing-the-waters meetings. In addition, the Company determined that dates ranging between January 31, 2024 and September 30, 2024 were the most likely dates to complete an IPO and the Company used these dates to calculate the present value as of each valuation date in each IPO scenario. The dissolution scenario was assigned a $0 value given that if the Company’s clinical trials failed, with no other assets beyond cretostimogene, any cash on hand after satisfying liabilities would be used in its entirety to pay liquidation preferences to the holders of redeemable convertible preferred stock. In order for the Board to determine the estimated fair value of the Company’s common stock, the Company obtained independent third-party valuations of its common stock as of June 30, 2022 (the “June 30, 2022 Valuation”), April 30, 2023 (the “April 30, 2023 Valuation”), July 31, 2023 (the “July 31, 2023 Valuation”), September 20, 2023 (the “September 20, 2023 Valuation”), October 27, 2023 (the “October 27, 2023 Valuation”) and December 4, 2023 (the “December 4, 2023 Valuation”). At each option grant date, the Board considered whether any events occurred that would trigger any material changes to the business or would require adjustment to the estimated fair value from the previous valuation date. The Company does not expect to make any additional grants prior to the completion of its IPO other than grants made concurrent with the IPO at an exercise price equal to the final IPO price (if any). The Board, with input from management, determined the fair value of the Company’s common stock to be $0.24 per share for options granted in October and December 2022 and March 2023, after considering the June 30, 2022 Valuation. For the June 30, 2022 Valuation, the Company utilized the OPM to derive the implied equity value for the Company. For the OPM, the market approach, utilizing the backsolve method, was used to determine the implied total enterprise value of the Company by accounting for all share class rights and preferences. For purposes of the June 30, 2022 Valuation, the backsolve method reflected the Company’s sale and issuance of 112,422,700 shares of Series E redeemable convertible preferred stock in the Series E financing in September 2022 and October 2022, at a purchase price of $1.0674 per share, for aggregate gross proceeds of approximately $120 million. In addition, an option-based approach based on the Finnerty Model was performed to estimate the appropriate discount for lack of marketability (“DLOM”) for the common stock. A DLOM of 27.6% was used for the June 30, 2022 Valuation. For the period from the date of the June 30, 2022 Valuation to March 15, 2023, the Board determined there were no internal or external developments since the date of such valuation that warranted a change in the estimated fair value of the common stock, other than the Company’s Series E redeemable convertible preferred stock financing that was already reflected in the The Board, with input from management, determined the fair value of the Company’s common stock to be $0.39 per share as of June 14, 2023, after considering the April 30, 2023 Valuation. In reaching this determination, the Board determined that no material changes had occurred in the business since the date of the third-party valuation report, and that the forecasted financial information reviewed as part of the April 30, 2023 Valuation was still appropriate. Among the qualitative factors considered by the Board in determining the fair value of the Company’s common stock were the following developments in the Company’s business subsequent to March 15, 2023: • continued progress in the Company’s ongoing clinical trials, including: enrollment of patients in the Phase 3 BOND-003 clinical trial; positive data announced at the American Urological Association conference from the Phase 2 CORE-001 clinical trial; and the secondary sales of the Company’s common stock, as described below. As a result of the developments described above, the Company concluded it was appropriate to incorporate various IPO scenarios into the valuation. As discussed above, the valuation analysis was performed using the PWERM to establish the following scenarios and relative weightings and values, as well as taking into account the secondary sale of an aggregate of 17,747,000 shares of the Company’s common stock to investors for a per share purchase price of $0.80 (the “Secondary Common Stock Transaction”). Concluded PWERM Fair Value (80% weighting) Secondary Common Stock Transaction (20% weighting) Each DLOM was based on the application of the Finnerty or Average Strike put option analysis. The Company estimated the expected timing of a potential liquidity event was 2.0 years in the Remain Private Scenario and 1.0 and 1.42 years in the Early IPO and Late IPO Scenarios, respectively, based on management’s best estimates and an analysis of market conditions. The Company utilized a $[***] million equity value for each of the IPO scenarios included in the table above. The Board, with input from management, determined the fair value of the Company’s common stock to be $0.53 per share as of August 15, 2023, after considering the July 31, 2023 Valuation. In reaching this determination, the Board determined that no material changes had occurred in the business since the date of the third-party valuation report, and that the forecasted financial information reviewed as part of the July 31, 2023 Valuation was still appropriate. considered by the Board in determining the fair value of the Company’s common stock were the following developments in the Company’s business subsequent to June 14, 2023; continued progress in the Company’s ongoing clinical trials, including increased enrollment in the Company’s Phase 3 BOND-003 clinical trial; and the closing of the Company’s Series F redeemable convertible preferred stock financing in July 2023. As discussed above, the valuation analysis was performed using the PWERM to establish the following scenarios and relative weightings and values, as well as taking into account the Secondary Common Stock Transaction (with a reduced weighting compared to the April 30, 2023 Valuation given the elapsed period of time since the Secondary Common Stock Secondary Common Stock Transaction (15% weighting) Remain Private Scenario and 0.75 and 1.17 years in the Early IPO and Late IPO Scenarios, respectively, based on management’s best estimates and an analysis of market conditions. The Company continued to utilize a $[***] million equity value for each of the IPO scenarios included in the table above. The Board, with input from management, determined the fair value of the Company’s common stock to be $0.70 per share as of October 9, 2023, after considering the September 20, 2023 Valuation. In reaching this determination, the Board determined that no material changes had occurred in the business since the date of the third-party valuation report, and that the forecasted financial information reviewed as part of the September 20, 2023 Valuation was still appropriate. considered by the Board in determining the fair value of the Company’s common stock were the following developments in the Company’s business subsequent to August 15, 2023: continued progression in the Company’s ongoing clinical trials; and the Company’s IPO organizational meeting held on September 20, 2023. As discussed above, the valuation analysis was performed using the PWERM to establish the following scenarios and relative weightings and values. Remain Private Scenario and 0.44 and 0.78 years in the Early IPO and Late IPO Scenarios, respectively, based on management’s best estimates and an analysis of market conditions. Timing of the IPO scenarios were specifically adjusted to align with changes in management’s IPO plan from the July 31, 2023 Valuation. Additionally, this valuation reflects that the Company held the organizational meeting for the IPO on September 20, 2023, indicating an increased probability of an IPO occurring. The Company continued to utilize a $[***] million equity value for each of the IPO scenarios included in the table above. The Board, with input from management, determined the fair value of the Company’s common stock to be $0.82 per share as of November 20, 2023, after considering the October 27, 2023 Valuation. In reaching this determination, the Board determined that no material changes had occurred in the business since the date of the third-party valuation report, and that the forecasted financial information reviewed as part of the October 27, 2023 Valuation was still appropriate. Among the qualitative factors considered by the Board in determining the fair value of the Company’s common stock was the continued progression of the Company’s Phase 3 BOND-003 clinical trial. As discussed above, the valuation analysis was performed using the PWERM to establish the following scenarios and relative weightings and Remain Private Scenario and 0.34 and 0.68 years in the Early IPO and Late IPO Scenarios, respectively, based on management’s best estimates and an analysis of market conditions. Additionally, this valuation reflects the fact that the Company confidentially submitted a draft registration statement for the IPO on October 27, 2023, indicating an increased probability of an IPO occurring. The Company continued to utilize a $[***] million equity value for each of the IPO scenarios included in the table above. The Board, with input from management, determined the fair value of the Company’s common stock to be $1.32 per share as of December 13, 2023, after considering the December 4, 2023 Valuation. In reaching this determination, the Board determined that no material changes had occurred in the business since the date of the third-party valuation report, and that the forecasted financial information reviewed as part of the December 4, 2023 Valuation was still appropriate. factors considered by the Board in determining the fair value of the Company’s common stock were the following developments in the Company’s business subsequent to October 9, 2023: the Company confidentially filed the first amendment of registration statement related to a potential IPO with the Commission; and positive interim data from the Company’s Phase 3 BOND-003 clinical trial was reported at the 24th Annual Meeting of Society of Urologic Oncology (SUO) on November 30, 2023 (the “SUO Data”). As discussed above, the valuation analysis was performed using the PWERM to establish the following scenarios and relative weightings and The Company estimated the expected timing of a potential liquidity event was 1.5 years in the Remain Private Scenario and 0.16 years in the IPO Scenario, based on management’s best estimates and an analysis of market conditions. Additionally, this valuation reflects the positive feedback the Company has received from investors related to the SUO Data and that the Company confidentially submitted an amended draft registration statement for the IPO on December 4, 2023, both indicating an increased probability of an IPO occurring. As a result, the Company assumed only one IPO scenario occurring in January 2024. The Company utilized a $[***] million equity value for the IPO scenario. COMPARISON OF MOST RECENT VALUATIONS AND PRELIMINARY ASSUMED IPO PRICE As noted above, the Preliminary Price Range is between $[***] and $[***] (without giving effect to any reverse stock split that the Company will effect prior to the offering). The Company notes that, as is typical in IPOs, the estimated price range for the IPO was not derived using a formal determination of fair value, but was determined by discussions between the Company and the lead underwriters. The Company’s most recent grants of stock options were for an aggregate of 2,950,000 shares made on December 13, 2023 with an exercise price of $1.32 per share, which the Board determined to be the fair value of its common stock on that date (the “Estimated Fair Value”). As is typical in IPOs, the Preliminary Price Range was based in part on the lead underwriters’ quantitative and qualitative analysis that differs from the valuation methodology used by the Company and its independent third-party valuation firm. Among the factors that were considered in setting the Preliminary Price Range were the following: an analysis of the typical valuation ranges seen in comparable public companies in the Company’s industry, as well as a broader set of valuation ranges seen in recent IPOs; the improving condition of the securities markets, particularly the Nasdaq Biotechnology Index, and the recent market prices of publicly traded common stock of comparable companies; favorable feedback received from potential investors from the Company’s testing-the-waters meetings; an assumption that there would be a receptive public trading market for a late clinical-stage biopharmaceutical company such as the Company; and an assumption that there would be sufficient demand for the Company’s common stock to support an offering of the size contemplated by the Company. The Company respectfully submits that, in addition to the above factors, the difference between the most recent estimated fair values of the Company’s common stock as determined by the Board and the Preliminary Price Range, if obtained, is that the hybrid valuation method used by the Company to determine such estimated fair values since June 2023 reflects the potential that the Company might remain a privately held company or have its clinical trials fail (dissolution scenario), as applicable, which inherently decreases the Estimated Fair Value per share of the Company’s common stock due to the combination of (i) the lower equity value in the Remain Private Scenario and the discounting to present value and (ii) the application of a DLOM. Conversely, the Preliminary Price Range necessarily assumes only a single potential liquidity event, the IPO in January 2024, and does not include a DLOM as an active trading market for the Company’s common stock will exist following the IPO. As a result, the Preliminary Price Range was neither reduced by the expected fair value from other potential future scenarios nor discounted for lack of marketability. Additionally, the Preliminary Price Range assumes the conversion of all of the Company’s redeemable convertible preferred stock into common stock in connection with the completion of the IPO. The corresponding elimination of the preferences and rights enjoyed by the holders of such convertible preferred stock results in a higher valuation of the common stock in the Preliminary Price Range, and also drives a lower common stock value in the non-IPO scenario. Notably, the implied equity value of $[***] million and estimated future value per share of $[***] utilized in the IPO scenario used to determine the Estimated Fair Value is consistent with the Preliminary Price Range and implied equity value of $[***] million at the midpoint of the Preliminary Price Range. Based on the Preliminary Price Range, the current status of the financial markets and continued uncertainty as to whether the Company will be able to complete its planned IPO within the Preliminary Price Range, the Company believes that the estimated fair values of its common stock as determined by the Board since October 2022 are consistent with the increasing value of its common stock in connection with its progression towards an IPO. In light of the above, the Company respectfully submits that the deemed per share fair values used as the basis for determining stock-based compensation expense in connection with its grants of equity awards are reasonable and appropriate for the reasons described herein and in the Registration Statement. The Company also refers you to the discussion of its general approach of determining fair value of equity awards set forth in the Registration Statement under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Significant Judgments and Estimates – Stock-Based Compensation” for additional background regarding its equity grant valuation methodologies to date. The Company respectfully requests that the information contained in this request letter be treated as confidential information and that the Commission provide timely notice to Arthur Kuan, Chief Executive Officer, CG Oncology, Inc., 400 Spectrum Center Dr., Suite 2040, Irvine, CA 92618, telephone (949) 409-3700, before it permits any disclosure of the highlighted information contained in this request letter.

One letter for all the questions, without numbered answers. Read the reply
Prospectus Summary · Overview, page 1
SEC asked (2)
We note your disclosure that you have observed "encouraging interim results in [y]our ongoing open-label Phase 2 CORE-001 clinical trial of cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients." Please remove the term “encouraging” here, and elsewhere, regarding the results as this may create an inference that a product candidate is more likely to be found to be safe and
Rest of the question

effective. Please limit the discussion to the objective clinical data, such as the endpoints.

CGON answered

See the reply above.

Prospectus Summary · Overview, page 1
SEC asked (3)
We note your reference to interim results. Please revise your disclosure to note, as you do on page 26, that interim, topline or preliminary results that you report may differ from future results of the same studies or trials.
CGON answered

See the reply above.

Prospectus Summary · Overview, page 1
SEC asked (4)
Please specify whether the referenced trials, here and elsewhere, were powered for statistical significance.
CGON answered

See the reply above.

Prospectus Summary · Overview, page 1
SEC asked (5)
Please disclose whether any of the observations of adverse events from the trials were considered serious adverse events. In addition, please advise, if true, that adverse events greater than or equal to Grade 3 TRAEs are considered serious adverse events or otherwise advise.
CGON answered

See the reply above.

Prospectus Summary · Overview, page 1
SEC asked (6)
We note that in your ongoing open-label Phase 2 CORE-001 clinical trial, you observed "one TRAE leading to a patient discontinuation of pembrolizumab." Please revise your disclosure to specify the type of TRAE that was observed and how it was graded.
CGON answered

See the reply above.

Management's Discussion and Analysis of Financial Condition and Results of Operations · Results of Operations, page 88
SEC asked (7)
To the extent you track research and development expenses by indication or treatment setting as depicted in your pipeline table, revise to provide a breakdown on that basis. If you do not track by indication or treatment setting, disclose that fact.
CGON answered

See the reply above.

Critical Accounting Policies and Significant Judgments and Estimates · Stock-Based Compensation, page 93
SEC asked (8)
Once you have an estimated offering price or range, please explain to us how you determined the fair value of the common stock underlying your equity issuances and the reasons for any differences between the recent valuations of your common stock leading up to the initial public offering and the estimated offering price.
Rest of the question

This information will help facilitate our review of your accounting for equity issuances including stock compensation. Please discuss with the staff how to submit your response. Revise your MD&A as well as Recent Sales of Unregistered Securities section on page II-2 to provide a tabular presentation of your option grants and how they were valued.

CGON answered

See the reply above.

Combination of Cretostimogene Plus Pembrolizumab for High-risk BCG-unresponsive CIS- · containing NMIBC, page 113
SEC asked (9)
We note your disclosure regarding the clinical trial collaboration and supply agreement with Merck. Please describe the material terms of this agreement, and file this agreement in accordance with Item 601(b)(10) of Regulation S-K, or otherwise advise. Intellectual Property, page 118
CGON answered

See the reply above.

Combination of Cretostimogene Plus Pembrolizumab for High-risk BCG-unresponsive CIS- · containing NMIBC, page 113
SEC asked (10)
Please revise your disclosure to specify the nature of your pending patent applications (e.g., composition of matter, method of use or process). Management
CGON answered

See the reply above.

Executive Officers and Directors, page 129
SEC asked (11)
We note your disclosure that Mr. DiPalma worked as a consultant and senior advisor since March 2021 and became CFO in March 2023. We also note your disclosure on page 158 that Mr. DiPalma is a managing director at Danforth and appears to be compensated through this position. Please revise your disclosure to clarify whether Mr. DiPalma is working on a full-time basis for your company.
CGON answered

See the reply above.

General
SEC asked (12)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
CGON answered

See the reply above.

Prospectus Summary · Overview, page 1
SEC asked (1)
We note your disclosure on page 2 that cretostimogene has received fast track designation from the FDA for the treatment of high-risk, BCG-unresponsive NMIBC patients. Please provide balancing disclosure, as you note on page 28, that fast track designation by the FDA for cretostimogene may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that
Rest of the question

cretostimogene or any future product candidate which may receive fast track designation will receive marketing approval.

CGON answered
CG Oncology’s Response: The Company has revised page 2 of the Registration Statement in response to the Staff’s comment.

Summary Financial Data

Balance Sheet Data,
Read in the reply
Summary Financial Data · Balance Sheet Data, page 13
SEC asked (2)
Your disclosure on page 13 states that pro forma column gives effect to the automatic conversion of all outstanding shares of your redeemable convertible preferred stock into an aggregate of 366,277,131 shares of common stock. However, it appears the conversion of your Series F redeemable convertible preferred stock has not been reflected in pro forma stockholders’ equity.
Rest of the question

Please explain why the automatic conversion of your Series F redeemable convertible preferred stock has not been reflected in pro forma stockholders’ equity, and revise to address this apparent inconsistency between these disclosures. Capitalization, page 80

CGON answered
CG Oncology’s Response: The Company has revised page 13 of the Registration Statement in response to the Staff’s comment.
Read in the reply
Summary Financial Data · Balance Sheet Data, page 13
SEC asked (3)
Your disclosure on page 80 states that your pro forma column reflects "the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into 366,277,131 shares of our common stock." However, it does not appear as though your Series F redeemable convertible preferred stock that was issued on July 28, 2023 has been included in your actual or pro forma columns.
Rest of the question

Please revise to address this apparent inconsistency.

CGON answered
Oncology’s Response: The Company has revised page 80 of the Registration Statement in response to the Staff’s comment.
Read in the reply
Management · Executive Officers, page 133
SEC asked (4)
We note your response to comment 11, including your revised disclosure on page 134 that Mr. DiPalma works on a part-time basis as your CFO. Please include risk factor disclosure concerning Mr. DiPalma's part-time status and the number of hours of service hours per month he is expected to provide.
CGON answered
CG Oncology’s Response: The Company’s respectfully advises the Staff that while technically part time, Mr. DiPalma plans to devote the necessary hours to manage the Company’s accounting team and financial reporting following the completion of the offering and listing on the Nasdaq stock exchange. The Company expects that Mr. DiPalma’s level of support will be substantially on par with the level that a full-time CFO would spend supporting a public company.
Rest of the answer

The Company has revised page 43 of the Registration Statement in response to the Staff’s comment, including to reflect the foregoing.

*********

Any comments or questions regarding the foregoing should be directed to the undersigned at (858)

523-3962. Thank you in advance for your cooperation in connection with this matter.

Read in the reply

Letters without questions

Other letters

UPLOAD and CORRESP
5 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 9 letters filed since 2023-11-27. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CGON/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.